Premenopausal osteoporosis

References

• WHO Study Group: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organization; 1994.
   Google Scholar
• Kanis J, Melton LJ, 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–1141.
   PubMed Web of Science ®Google Scholar
• Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–1259.
   PubMed Web of Science ®Google Scholar
• Wigderowitz CA, Cunningham T, Rowley DI, et al. Peripheral bone mineral density in patients with distal radial fractures. J Bone Joint Surg Br. 2003;85:423–425.
   PubMedGoogle Scholar
• Hung LK, Wu HT, Leung PC, et al. Low BMD is a risk factor for low-energy Colles' fractures in women before and after menopause. Clin Orthop Relat Res. 2005 Jun;(435):219–225.
   PubMed Web of Science ®Google Scholar
• Pepe J, Body JJ, Ferrari S, et al. Osteoporosis in premenopausal women: a clinical narrative review by the ECTS and the IOF. J Clin Endocrinol Metab. 2020;105(8):2487–2506.
   Web of Science ®Google Scholar
• Cohen A. Premenopausal osteoporosis. Endocrinol Metab Clin North Am. 2017;46(1):117–133.
   PubMed Web of Science ®Google Scholar
• Abraham A, Cohen A, Shane E. Premenopausal bone health: osteoporosis in premenopausal women. Clin Obstet Gynaecol. 2013;56:722–729.
   Google Scholar
• Gourlay ML, Brown SA. Clinical considerations in premenopausal osteoporosis. Arch Intern Med. 2004;164:603–614.
   PubMedGoogle Scholar
• Shubart CR, Yeap SS, Shepherd JA, et al. Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom. 2019;22(4):453–471.
   PubMed Web of Science ®Google Scholar
• Karlsson MK, Ahlborg HG, Karlsson C. Maternity and bone mineral density. Acta Orthop. 2005;76:2–13.
   PubMed Web of Science ®Google Scholar
• Karlsson C, Obrant KJ, Karlsson M. Pregnancy and lactation confer reversible bone loss in humans. Osteoporos Int. 2001;12(10):828–834.
   PubMed Web of Science ®Google Scholar
• Sowers M, Corton G, Shapiro B, et. al. Changes in bone density with lactation. JAMA. 1993;269:3130–3135.
   PubMed Web of Science ®Google Scholar
• Khosla S, Lufkin EG, Hodgson SF, et al. Epidemiology and clinical features of osteoporosis in young individuals. Bone. 1994;15(5):551–555.
   PubMed Web of Science ®Google Scholar
• Moreira Kulak CA, Schussheim DH, McMahon DJ, et al. Osteoporosis and low bone mass in premenopausal and perimenopausal women. Endocr Pract. 2000;6(4):296–304.
   PubMedGoogle Scholar
• Cohen A, Fleischer J, Freeby MJ, et al. Clinical characteristics, and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center. J Womens Health (Larchmt). 2009;18(1):79–84.
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993–1000.
   PubMed Web of Science ®Google Scholar
• Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. N Engl J Med. 2018;379(26):2547–2556.
   PubMed Web of Science ®Google Scholar
• Schorr M, Thomas JJ, Eddy KT, et al. Bone density, body composition, and psychopathology of anorexia nervosa spectrum disorders in DSM-IV vs DSM-5. Int J Eat Disord. 2017;50(4):343–351.
   PubMed Web of Science ®Google Scholar
• Solmi M, Veronese N, Correll CU, et al. Bone mineral density, osteoporosis and fractures among people with eating disorders: a systematic review and meta-analysis. Acta Psychiatr Scand. 2016;133(5):341–351.
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016;19:313–315.
   PubMed Web of Science ®Google Scholar
• Tremollieres F. Impact of oral contraceptive on bone metabolism. Best Pract Res Clin Endocrinol Metab. 2013;27:47–53.
   PubMed Web of Science ®Google Scholar
• Goshtasebi A, Subotic Brajic T, Prior JC, et al. Adolescent use of combined hormonal contraception and peak bone mineral density accrual: a meta-analysis of international prospective controlled studies. Clin Endocrinol (Oxf). 2019;90(4):517–524.
   PubMed Web of Science ®Google Scholar
• Dombrowski S, Jacob L, Hadji P, et al. Oral contraceptive use and fracture risk – a retrospective study of 12 970 women in the UK. Osteoporos Int. 2017;28(8):2349–2355.
   PubMed Web of Science ®Google Scholar
• Kyriakakis I, Kostev K, Nassour T, et al. The impact of depot medroxyprogesterone acetate on fracture risk: a case control study from the UK. Osteoporos Int. 2017;28(1):291–297.
   PubMed Web of Science ®Google Scholar
• Hornstein MD, Surrey ES, Weisberg GW, et al. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol. 1998;91(1):16–24.
   PubMed Web of Science ®Google Scholar
• Ebert A, Dong L, Merz M. Dienogest 2 mg daily in the treatment of adolescents with clinically suspected endometriosis: the Visanne Study to Assess Safety in adolescents. J Pediatr Adolesc Gynecol. 2017;30:560–567.
   PubMed Web of Science ®Google Scholar
• Kyvernitakis I, Kostev K, Hadji P. The tamoxifen paradox: influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer. Osteoporos Int. 2018;29(11):2557–2564.
   PubMed Web of Science ®Google Scholar
• Stumpf U, Kostev K, Kyvernitakis J, et al. Incidence of fractures in young women with breast cancer: a retrospective cohort study. J Bone Oncol. 2019;18:100254.
   PubMed Web of Science ®Google Scholar
• Francis PA, Pagani O, Fleming GF, et al. SOFT and TEXT investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122–137.
   PubMed Web of Science ®Google Scholar
• Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol. 2011;22(12):2546–2555.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Bianchi ML, Eisman JA, et al. Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int. 2012;23(12):2735–2748.
   PubMed Web of Science ®Google Scholar
• Collet C, Ostertag A, Ricquebourg M, et al. Primary osteoporosis in young adults: genetic basis and identification of novel variants in causal genes. JBMR Plus. 2018;2(1):12–21.
   PubMedGoogle Scholar
• Peris P, Ruiz-Esquide V, Monegal A, et al. Idiopathic osteoporosis in premenopausal women. Clinical characteristics and bone remodelling abnormalities. Clin Exp Rheumatol. 2008;26:986–991.
   PubMed Web of Science ®Google Scholar
• Cohen A, Dempster D, Recker R, et al. Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab. 2011;96:3095.
   PubMed Web of Science ®Google Scholar
• Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–58.
   PubMed Web of Science ®Google Scholar
• Shin K, Park SH, Park W, et al. Monthly oral ibandronate reduces bone loss in Korean women with rheumatoid arthritis and osteopenia receiving long-term glucocorticoids: a 48-week double-blinded randomized placebo-controlled investigator-initiated trial. Clin Ther. 2017;39(2):268–278.
   PubMed Web of Science ®Google Scholar
• Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257–2276.
   PubMed Web of Science ®Google Scholar
• Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Care Res (Hoboken). 2017;69(8):1095–1110.
   PubMed Web of Science ®Google Scholar
• Robinson L, Aldridge V, Clark EM, et al. Pharmacological treatment options for low bone mineral density and secondary osteoporosis in anorexia nervosa: a systematic review of the literature. J Psychosom Res. 2017;98:87–97.
   PubMed Web of Science ®Google Scholar
• Miller KK, Meenaghan E, Lawson EA, et al. Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2011;96(7):2081–2088.
   PubMed Web of Science ®Google Scholar
• Shapiro CL, Halabi S, Hars V, et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011;47(5):683–689.
   PubMed Web of Science ®Google Scholar
• Kyvernitakis I, Kann PH, Thomasius F, et al. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial. Bone. 2018;114:109–115.
   PubMed Web of Science ®Google Scholar
• O'Sullivan SM, Grey AB, Singh R, et al. Bisphosphonates in pregnancy and lactation-associated osteoporosis. Osteoporos Int. 2006;17:1008–1012.
   PubMed Web of Science ®Google Scholar
• Li LJ, Zhang J, Gao P, et al. Clinical characteristics and bisphosphonates treatment of rare pregnancy- and lactation associated osteoporosis. Clin Rheumatol. 2018;37(11):3141–3150.
   PubMed Web of Science ®Google Scholar
• Laroche M, Talibart M, Cormier C, et al. Pregnancy-related fractures: a retrospective study of a French cohort of 52 patients and review of the literature. Osteoporos Int. 2017;28(11):3135–3142.
   PubMed Web of Science ®Google Scholar
• Bianchi ML, Colombo C, Assael BM, et al. Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate. Lancet Respir Med. 2013;1(5):377–385.
   PubMed Web of Science ®Google Scholar
• Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2014;3:CD002010.
   Google Scholar
• Yao L, Wang H, Dong W, et al. Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease: a meta-analysis. Medicine. 2017;96(3):e5861.
   PubMed Web of Science ®Google Scholar
• Bhardwaj A, Swe KM, Sinha NK, et al. Treatment for osteoporosis in people with β-thalassaemia. Cochrane Database Syst Rev. 2016;3:CD010429.
   PubMedGoogle Scholar
• Levy S, Fayez I, Taguchi N, et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone. 2009;44(3):428–430.
   PubMed Web of Science ®Google Scholar
• Machairiotis N, Ntali G, Kouroutou P, et al. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. Horm Mol Biol Clin Investig. 2019;40(2).
   PubMed Web of Science ®Google Scholar
• Sokal A, Elefant E, Leturcq T, et al. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case control study. Osteoporos Int. 2019;30(1):221–229.
   PubMed Web of Science ®Google Scholar
• Langdahl BL. Osteoporosis in premenopausal women. Curr Opin Rheumatol. 2017;29(4):410–415.
   PubMed Web of Science ®Google Scholar
• Fazeli PK, Wang IS, Miller KK, et al. Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa. J Clin Endocrinol Metab. 2014;99(4):1322–1329.
   PubMed Web of Science ®Google Scholar
• Hong N, Kim JE, Lee SJ, et al. Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis. Clin Endocrinol (Oxf). 2018;88(5):652–658.
   PubMed Web of Science ®Google Scholar
• Choe EY, Song JE, Park KH, et al. Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures. J Bone Miner Metab. 2012;30(5):596–601.
   PubMed Web of Science ®Google Scholar
• Cohen A, Shiau AS, Nair N, et al. Effect of teriparatide on bone remodeling and density in premenopausal idiopathic osteoporosis: a phase 2 trial. J Clin Endocrinol Metab. 2020;105(10):dgaa489.
   PubMed Web of Science ®Google Scholar